Acquires betapharm – Fourth largest company in Germany
Dr. Reddy’s acquires betapharm, the fourth-largest generic pharmaceuticals company in Germany, for a total enterprise value of
€ 480 million in cash. It is the largest acquisition ever made by an Indian company till date.
Click to read related memories
Obtains 180-day marketing exclusivity for Ondansetron. Becomes Dr. Reddy's second 180-day marketing exclusivity for a generic drug in the US market
The USFDA grants final approval to Dr. Reddy’s ANDA for Ondansetron Hydrochloride Tablets, 4 mg, 8mg, 16 mg and 24 mg.
Click to read related memories
Revenues touch USD 1 Billion in December 2006
Revenues touch USD 1 Billion in December 2006. Dr. Reddy’s becomes the fastest in Indian Pharma to reach this landmark.
Click to read related memories
© Dr. Reddy's Laboratories Ltd., 2010
Dr. Reddy’s. We see our investment in betapharm as a key strategic initiative towards becoming a mid-sized global pharmaceutical company with strong presence in all key pharmaceutical markets. This will help us build a strategic presence in Europe.
Founder Chairman, Dr.Reddy's